international atomic energy agency l 4 protection issues in clinical methodology

31
International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Upload: randolph-tucker

Post on 11-Jan-2016

215 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

International Atomic Energy Agency

L 4

PROTECTION ISSUES IN CLINICAL METHODOLOGY

Page 2: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 2

Answer True or False

• PET scans should be performed immediately following the 18F-FDG injection

• There are means of optimizing PET dose, such as by scaling activity by weight for paediatric patients

• It is important to assess the pregnancy status of all female subjects of child-bearing age before beginning any part of a PET/CT exam

Page 3: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 3

Objective

To become familiar with the basic PET/CT procedure from the patient perspective, including patient preparation, administration of the radiopharmaceutical, imaging and discharge of the patient. Factors that influence patient dose will also be considered especially for paediatric and female patients

Page 4: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 4

• Patient preparation

• Imaging

• Patient dose

• Paediatric considerations

• Female patients

Content

Page 5: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

International Atomic Energy Agency

4.1 Patient Preparation4.1 Patient Preparation

Page 6: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 6

Patient Preparation

• Fast (water only) for 6 hours before appointment

• IDD (Insulin dependent diabetics) normal diet, normal morning insulin

• Patient should be relaxed before procedure starts

• Bowel preparation can be given

Page 7: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 7

Pre-Administration of Radiopharmaceuticals

• Patient in gown (CT scan – no metal on patient)

• Lie patient in rest area to relax

• Perform glucose test

• Butterfly or cannula for venous access (contra-lateral side to site of concern)

• Explain the procedure to the patient before administering the dose

• Confirm ID of patient (name, date of birth and address) before administration

Page 8: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 8

Post-Administration of Radiopharmaceutical

• Allow patient to relax for 45-60 minutes post injection

• Talking can increase uptake in jaw/throat area

• Movement will increase the FDG to those muscles involved

• Soothing music and dim lights

• Use CCTV to monitor patient

• Empty bladder before scan

Page 9: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 9

0

1000

2000

3000

4000

5000

6000

7000

0 20 40 60 80

Time (mins)

Co

un

ts Plasma

Untrapped

Trapped

inject scan

FDG Scanning Protocol

rest

Page 10: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

International Atomic Energy Agency

4.2 Imaging4.2 Imaging

Page 11: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 11

The PET/CT Scan

CT

PET

Surveyscan CT

Reconstruction algorithm

Attenuation correction

PET Fused Image

Page 12: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 12

Scan Process

1.CT scout view performed 2.Full CT performed3.Patient moved further into scanner

and PET scan acquired

Page 13: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 13

Contrast CT

• Perform contrast CT immediately following PET/CT only if necessary

Page 14: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

International Atomic Energy Agency

4.3 Patient Dose4.3 Patient Dose

Page 15: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 15

Typical Activity Administered (UK)Investigation Chemical

form Administered Activity (MBq)

Effective Dose (mSv)

Tumour FDG 400 8

Brain FDG 250 5

Cardiac FDG 400 8

Bone Fluoride 250 6

Bone Tc-99m MDP 600 3

Cardiac Tc-99m MIBI 400 4

Page 16: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 16

Typical CT Scan Factors

• 80-140 kVp

• 10 to 300 mAs

• 0.3 to 1 sec

• Pitch 0.2 to 1.5

Page 17: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 17

Optimization of CT Dose

• Select appropriate kVp, mAs and pitch

• Scan minimum length needed to address diagnostic question

• For Attenuation Correction alone mAs can be reduced to 10. However, with reduced mA there is a potential for artefacts

Page 18: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 18

Other Considerations

• Has request also been made for CT ?

• Will PET/CT answer the diagnostic question?

• Is stand-alone CT really needed?

Page 19: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 19

To Reduce Effective Dose (PET)

• Administer correct activity

• Hydrated patient

• Frequent voiding of the bladder especially when the scan is completed

• For paediatric patients, scale activity by weight

• For paediatric patients, use 3D PET if possible to enable lower injected activity

Page 20: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 20

Repeat Scans

• Consider accumulative dose if patient is having repeat scans (monitoring treatment, disease progression)

Page 21: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

International Atomic Energy Agency

3.4 Paediatric Considerations3.4 Paediatric Considerations

Page 22: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 22

Activity to Children

The amount of activity to be administered to a child can be calculated by one of the following formulae (based on values for adults):

• body weight/70 kg

• body surface area/1.73 m2

• height/174 cm

Page 23: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 23

Fraction of the Adult Activity

0.0

0.2

0.4

0.6

0.8

1.0

1.2

0 4 8 12 16 20 24Age (years)

Frac

tion

of a

dult

activ

ity

BWHBSA

Page 24: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 24

European Association of Nuclear Medicine (EANM)

0

0,1

0,2

0,3

0,4

0,5

0,6

0,7

0,8

0,9

1

0 10 20 30 40 50 60

Body Weight (kg)

Fra

ctio

n o

f a

du

lt a

ctiv

ity

Paediatric Task Group European Association Nuclear Medicine members. A radiopharmaceutical schedule for imaging paediatrics. Eur J Med 127-9, 1990

Page 25: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 25

CT Dose Reduction for Paediatric Patients

• Reduce mAs or/and kVp

• Use dose reduction features – mAs modulation, etc.

• Increase pitch

• Reduce number of bed positions

Page 26: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

International Atomic Energy Agency

4.5 Female patients4.5 Female patients

Page 27: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 27

Female Patients

• Check clinical history

• Pregnancy status of all females 12-55 years should be known before administering the radiopharmaceutical

Page 28: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 28

Dose to Uterus

Investigation Chemical form Administered Activity (MBq)

Dose to Uterus (mGy)

Tumour FDG 400 8

Brain FDG 250 5

Cardiac FDG 400 8

Bone Fluoride 250 5

Bone Tc-99m MDP 600 4

Cardiac Tc-99m MIBI 400 3

Page 29: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 29

Pregnancy

• If patient unsure of pregnancy status, verify status

• If pregnant, contact Referrer and PET/CT consultant

• If subsequently found to be pregnant, refer to local Radiation Protection Advisor

Page 30: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 30

Breast Feeding

• Baby should be fed by mother just prior to mother’s FDG injection

• While FDG concentration in breast milk is low,

NONETHELESS• Advise that baby is fed by a third party up to

4hours after the injection to avoid dose to the baby due to close contact with mother

J Nucl Med 2001;42:1238-1242

Page 31: International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY

Radiation Protection in PET/CT 31

SUMMARY OF PROTECTION ISSUES IN CLINICAL METHODOLOGY

• PET scans require the patient to fast for 6 hours prior to 18F-FDG injection, and remain quiet for 1 hour afterward prior to the acquisition of the PET scan

• PET dose can be optimized by hydrating patient, requesting frequent voiding of the bladder after the scan, and for paediatric patients scaling activity by weight and using 3D PET if possible to enable lower injected activity

• CT dose can be optimized by selecting appropriate kVp and mAs depending on the diagnostic question which the CT is intended to answer

• As radiation risk is strongly age-dependent, it is especially important to assess the pregnancy status of all female subjects of child-bearing age before beginning any part of a PET/CT exam